The global Next Generation Sequencing (NGS) market size was valued at USD 4.62 billion in 2015 and is anticipated to experience significant growth over the forecast period. Development of more efficient and rapid genomic sequencing methodologies is anticipated to further drive adoption of NGS platforms consequently influencing industrial growth.
Growing automation in the pre-sequencing protocols is anticipated to drive progress in the market in the coming years. Utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is a significant factor which is expected to enhance demand for NGS over the forecast period.
UK NGS market revenue, by technology, 2013 - 2024 (USD Million)
An increasing number of R&D projects in the fields of metabolomics, proteomics, and transcriptomics are expected to boost demand for this technology as well. Proteomics and genomics operate on and with a huge array of structural information that needs to be collected and sorted by means of sequence determination and subsequent integrated data analysis.
The launch of novel products and services by prominent industry leaders is expected to influence growth over the forecast period. Moreover, rising inclination of scientists and drug developers towards the NGS technology in order to implement the approach of personalized medicine has proved to be a tidal wave for the demand of these platforms in order to gain insights into the genetic organization of a large number of organisms. This rise in demand is anticipated to drive the NGS market through to 2025.
Development of the products that focus on complete workflow from sampling to report generation post data interpretation is attributive to drive growth. Innovative commercial models such as price-per-insight options offer labs better cost management and low initial investment hurdles with this product thus driving adoption rate of the product
Application, wise NGS technology, finds lucrative avenues in developmental oncology, prenatal and preimplantation genetic screening, HLA typing/immune system monitoring, metagenomics, epidemiology & drug development, aggri genomics & forensics, consumer genomics, and clinical investigation.
Global next generation sequencing market by applications, 2015 & 2025 (USD Million)
Oncology is anticipated to witness lucrative growth in the coming years as a consequence of the rapid development of sequencing capabilities which enables targeted sequence determination of a number of cancer genes that enable oncologists to access genetic information present in some of the less accessible dense gene clusters related to cancer cells and tumors.
Targeted sequencing accounted for the dominant share owing to the presence of several benefits associated with a smaller dataset and reduction in sequencing costs. Furthermore, growth in the number of protein expression analysis projects are expected to rise owing to the presence of large sets of DNA-based sequence data.
Whole genome sequencing (WGS) which includes genome, microbial and de novo genome applications is expected to witness fastest year on year growth owing to an increased number of research programs aimed at mapping human and non-human whole genomes combined with reducing costs of WGS.
Sequencing dominated with respect to revenue share in 2015 and is expected to maintain its dominance over the forecast period. Following this step, data analysis is anticipated to witness significant growth as compared to rest of workflow steps owing to the presence of considerable activities for development of novel algorithms and their up gradation in order to provide rapid results after data analysis.
With the expected increase in implementation of WGS, subsequent data generation is expected to grow exponentially. However, continuing reduction in cost is expected to result in the generation of large amounts of big data. Consequentially, data analysis is expected to become the bottle neck for genomic and proteomic R&D projects over the forecast period lest more robust and efficient data storage, and management methods are put in place.
Application of these solutions in research projects that are carried out in the universities and research centers are attributive for the largest share owing to the presence of a large number of R&D projects. Provision of on-site bioinformatics courses that involve the workshops on the practical implementation of NGS and data analysis are also expected to boost revenue generated through academic research in the coming years.
Growing adoption of NGS-based smaller scale platforms for clinical diagnostics is also a significant end market expected to drive demand over the coming decade. Key market participants are actively targeting small laboratories and clinics by introducing high performance small benchtop sequencers that are expected to enhance NGS adoption in an increasing number of routine disease diagnostics and monitoring procedures.
North America NGS market accounted for the largest share in 2015. This large share can be accounted for by the presence of an enhanced technological healthcare framework, growing adoption of reduction in the cost of sequencing per base pair, and high R&D investment for genomic and proteomic sequence determination for biomarkers research.
Moreover, the majority of respondents for academic & clinical use are located in the U.S., Germany, and UK owing to presence of several universities that offer molecular biology courses in this region thereby affecting growth in North American and European NGS industry.
For instance, in June 2015, Illumina Inc. inaugurated its European headquarters in Cambridge in order to gain the larger share of revenue generated through 10,000 genome project carried out in UK and enhance presence in the home market of a direct major rival.
Asia Pacific is expected to grow at the fastest rate with a CAGR of over 18% throughout the forecast period owing to increasing investment for development of healthcare, growing medical awareness in the regional population, and growing per capita and residual income levels.
Key market contributors operating herein include Pacific Biosciences, Beijing Genomics Institute, Illumina Inc., F Hoffman-La Roche, GATC Biotech AG., Thermo Fisher Scientific, Oxford Nanopore Technologies Inc., Agilent Technologies Inc., Biomatters Ltd., DNAStar Inc., Macrogen Inc., Helicos BioSciences, CLC Bio (Qiagen), and Knome Inc.
The competition between organizations seeking to gain a foothold in the fast-developing biotech sector is waging on multiple battlefields. Organizations are focusing on the introduction of inexpensive sequencing devices in routine medical checkups.
For instance, Grail (a spin-off company from Illumina) is focusing on the development of an NGS technology that allows detection of different types of cancer before the symptoms appear. This test is projected to reach the market in 2019. Furthermore, companies are also engaged in endeavors for commodifying genomic data by making it available to research laboratories worldwide.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2016 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific or additional market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the next generation sequencing market on the basis of application, technology, workflow, end-use and region:
Application Outlook (Revenue, USD Million; 2014-2025)
Non-Communicable / Other Diseases
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Technology Outlook (Revenue, USD Million; 2014-2025)
Targeted Sequencing Analysis
Workflow Outlook (Revenue, USD Million; 2014-2025)
NGS Library Preparation Kits
NGS Semi-Automated Library Preparation
NGS Automated Library Preparation
Primary Data Analysis
Secondary Data Analysis
Tertiary Data Analysis
End-use Outlook (Revenue, USD Million; 2014-2025)
Hospitals & Clinics
Pharma & Biotech Entities
Regional Outlook (Revenue, USD Million; 2014-2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."